Natalizumab Completed Phase 1 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) / Secondary Progressive Multiple Sclerosis (SPMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00559702Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
NCT01884935PK and PD Study of Natalizumab in Pediatric Subjects With RRMS